Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:1392 | Oxidative Stress |
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.17 | KE:768 | Increase, Cytotoxicity |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.2 | KE:796 | Increase, Hyperplasia (urothelial) |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.14 | KE:768 | Increase, Cytotoxicity |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1065 | Activation, estrogen receptor alpha |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.12 | KE:1262 | Apoptosis |
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.17 | KE:1262 | Apoptosis |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1392 | Oxidative Stress |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.14 | KE:155 | Inadequate DNA repair |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1614 | Decrease, androgen receptor activation |
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.2 | KE:155 | Inadequate DNA repair |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1669 | Increased, DNA damage and mutation |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:592 | Reduced, survival |
KE:10042 | Abnormal development | |||||
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1769 | Increase, Body fluid overload |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.2 | KE:796 | Increase, Hyperplasia (urothelial) |
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.12 | KE:1669 | Increased, DNA damage and mutation |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.09 | KE:155 | Inadequate DNA repair |
AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary System Disease | Under Development | 0.2 | KE:1392 | Oxidative Stress |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:1973 | Increased, estrogens |
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
KE:1262 | Apoptosis | |||||
KE:1392 | Oxidative Stress | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.06 | KE:1392 | Oxidative Stress |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1669 | Increased, DNA damage and mutation |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.18 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.11 | KE:1262 | Apoptosis |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.18 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous System Disease | - | 0.05 | KE:1392 | Oxidative Stress |
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.25 | KE:748 | Increased, Estrogen receptor (ER) activity |
KE:2050 | Increase, developmental abnormalities | |||||
AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities |
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.2 | KE:155 | Inadequate DNA repair |
KE:1392 | Oxidative Stress | |||||
AOP:479 | Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.14 | KE:1392 | Oxidative Stress |
AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal System Disease | Under Review | 0.14 | KE:1392 | Oxidative Stress |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.12 | KE:1392 | Oxidative Stress |
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.17 | KE:1262 | Apoptosis |
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:1392 | Oxidative Stress |
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 0.14 | KE:1262 | Apoptosis |
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:1392 | Oxidative Stress |
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.14 | KE:1392 | Oxidative Stress |
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:1392 | Oxidative Stress |
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.06 | KE:1392 | Oxidative Stress |
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.22 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.22 | KE:1262 | Apoptosis |
KE:1392 | Oxidative Stress | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.08 | KE:1392 | Oxidative Stress |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.2 | KE:827 | sensitisation, skin |
AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival |
AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.14 | KE:636 | Decreased, survival |
AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive System Disease | - | 0.17 | KE:330 | Decrease, Fertility |
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.17 | KE:1262 | Apoptosis |
AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | 0.12 | KE:636 | Decreased, survival |
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer |
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer |
AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | 0.17 | KE:2147 | Decreased, Viable Offspring |
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:2129 | Metabolically unhealthy Obesity |
AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.4 | KE:885 | Increase, Cancer |
KE:1392 | Oxidative Stress | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.29 | KE:2147 | Decreased, Viable Offspring |
KE:1392 | Oxidative Stress | |||||
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.33 | KE:885 | Increase, Cancer |
KE:1392 | Oxidative Stress | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.17 | KE:18 | Activation, AhR |
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.14 | KE:18 | Activation, AhR |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.08 | KE:18 | Activation, AhR |
AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune System Disease; Musculoskeletal System Disease | Under Development | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.33 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.4 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.25 | KE:1392 | Oxidative Stress |
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:18 | Activation, AhR |
KE:1669 | Increased, DNA damage and mutation | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.6 | KE:18 | Activation, AhR |
KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | |||||
KE:1669 | Increased, DNA damage and mutation | |||||
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:18 | Activation, AhR |
KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:18 | Activation, AhR |
KE:1262 | Apoptosis | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR |
KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.17 | KE:1392 | Oxidative Stress |
AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive System Disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.17 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway |
KE:1392 | Oxidative Stress | |||||
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:18 | Activation, AhR |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:18 | Activation, AhR |
KE:1392 | Oxidative Stress | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.11 | KE:1392 | Oxidative Stress |
AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical Disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal System Disease | - | 0.17 | KE:18 | Activation, AhR |
AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive System Disease; Cancer | Under Review | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
AOP:523 | Retinoic acid receptor agonism during neurodevelopment leading to microcephaly | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.33 | KE:18 | Activation, AhR |
KE:1262 | Apoptosis |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.4 | KE:26 | Antagonism, Androgen receptor |
KE:337 | N/A, Impairment of reproductive capacity | |||||
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:18 | Activation, AhR |
KE:947 | Increase, Early Life Stage Mortality | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.29 | KE:18 | Activation, AhR |
KE:947 | Increase, Early Life Stage Mortality | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.44 | KE:18 | Activation, AhR |
KE:1971 | Increased, tumor growth | |||||
KE:1262 | Apoptosis | |||||
KE:1982 | metastatic breast cancer | |||||
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.3 | KE:1669 | Increased, DNA damage and mutation |
KE:155 | Inadequate DNA repair | |||||
KE:1982 | metastatic breast cancer | |||||
AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal System Disease | Under Review | 0.33 | KE:18 | Activation, AhR |
KE:947 | Increase, Early Life Stage Mortality | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.33 | KE:18 | Activation, AhR |
KE:947 | Increase, Early Life Stage Mortality |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.